This section of the web-site contains information on medicines, advertising of which is not foreseen by the legislation. Information in this section is intended for reference only, has exclusively scientific and informative character and should not be treated as advertising information for a wide range of people. According to the current legislation, access to this information is granted to medical and pharmaceutical employees. Please confirm that you are a medical or pharmaceutical employee.


Ursofalk (Ursodeoxycholic acid) is the gold standard for the treatment of cholestatic liver diseases and cholesterol gallstones. Back in 1981, a group of gastroenterologists from Frankfurt (Germany), headed by Prof.

W. Leyschner, successfully used Ursofalk to dissolve gallstones in patients with chronic hepatitis1.

Ursodeoxycholic acid is a hydrophilic, non-cytotoxic bile acid, whose content in human bile is about 1%. It is the least aggressive bile acid – a natural component of human bile1. 
The main properties of ursodeoxycholic acid:

  • litholytic
  • immunomodulatory
  • antiapoptotic
  • hepatoprotective
  • antifibrotic
  • anti-inflammatory, hypocholesterolemic, canceropreventive

Ursofalk – the original German drug ursodeoxycholic acid, which is registered in 74 countries of the world and has been successfully used in practice for over 35 years. It is used as an abstract drug when registering ursodeoxycholic acid preparations.

The use of Ursofalk in patients with primary biliary cirrhosis can increase survival, slow the progression of the disease and prevent the occurrence of complications 2-4.

1. Ursofalk also dissolves cholesterol gallstones and reduces the concentration of cholesterol in the bile, allowing to reduce or arrest dyspeptic symptoms5,6.Ursofalk® in clinical practice – Freiburg: Dr. Falk Pharma GmbH, 2010.
2. Leuschner U. et al. The effect of the ursodeoxycholic acid is after the biliary cirrhosis. J Hepatol. 1994; 21 (4): 624-33.
3. Lindor K.D. et al. Effects of Ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology 1996; 110: 1515–1518.
4. Lindor K.D. et al. Ursodeoxycholic acid delays the onset of esophageal varices in primary biliary cirrhosis. Mayo Clin Proc. 1997; 72 (12): 1137-40.
5. Stiehl E.T. et al. For gallstone patients treated with chenodeoxycholic acid and / or ursodeoxycholic acid. Gastroenterology 79: 1192-119189, 1980.
6. Ventura P. et al. It is a double-blind controlled test for the treatment of dyspeptic disorders associated with gallstones or other hepatic disorders. Clinical Drug Investigation, 1996; 11 (2), 77–83.